<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Strategic</title>
	<atom:link href="http://www.tapanray.in/tag/strategic/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>US Biosimilar Overhaul: A Breakthrough Moment or a Strategic Test for Indian Pharma</title>
		<link>http://www.tapanray.in/us-biosimilar-overhaul-a-breakthrough-moment-or-a-strategic-test-for-indian-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=us-biosimilar-overhaul-a-breakthrough-moment-or-a-strategic-test-for-indian-pharma</link>
		<comments>http://www.tapanray.in/us-biosimilar-overhaul-a-breakthrough-moment-or-a-strategic-test-for-indian-pharma/#comments</comments>
		<pubDate>Sun, 09 Nov 2025 08:01:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Breakthrough]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[moment]]></category>
		<category><![CDATA[overhaul]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reform]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[test]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10996</guid>
		<description><![CDATA[On 31 October 2025, the Economic Times (ET) headline— “US biosimilar norms to keep local drug cos in good health” - quickly became one of the most discussed topics across India’s biopharmaceutical circles. For India, which is transitioning from a global generics’ powerhouse &#8230; <a href="http://www.tapanray.in/us-biosimilar-overhaul-a-breakthrough-moment-or-a-strategic-test-for-indian-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/us-biosimilar-overhaul-a-breakthrough-moment-or-a-strategic-test-for-indian-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Navigating Potential US Tariffs: Challenges and AI-Driven Opportunities for Indian Pharma</title>
		<link>http://www.tapanray.in/navigating-potential-us-tariffs-challenges-and-ai-driven-opportunities-for-indian-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=navigating-potential-us-tariffs-challenges-and-ai-driven-opportunities-for-indian-pharma</link>
		<comments>http://www.tapanray.in/navigating-potential-us-tariffs-challenges-and-ai-driven-opportunities-for-indian-pharma/#comments</comments>
		<pubDate>Sat, 09 Aug 2025 08:09:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[challenged]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recommendations]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tariff]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10955</guid>
		<description><![CDATA[India’s pharmaceutical industry, reportedly supplying 47% of US generic drugs and exporting $27.9 billion in FY24, faces the threat of 10-25% US tariffs under a potential Trump policy. Major players like Sun Pharma, Dr. Reddy’s, Cipla, Lupin, and Aurobindo, reportedly &#8230; <a href="http://www.tapanray.in/navigating-potential-us-tariffs-challenges-and-ai-driven-opportunities-for-indian-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/navigating-potential-us-tariffs-challenges-and-ai-driven-opportunities-for-indian-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Great Indian Pharma Consolidation: A Strategic Imperative for Global Ambition</title>
		<link>http://www.tapanray.in/the-great-indian-pharma-consolidation-a-strategic-imperative-for-global-ambition/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-great-indian-pharma-consolidation-a-strategic-imperative-for-global-ambition</link>
		<comments>http://www.tapanray.in/the-great-indian-pharma-consolidation-a-strategic-imperative-for-global-ambition/#comments</comments>
		<pubDate>Fri, 04 Jul 2025 00:00:01 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CDMA]]></category>
		<category><![CDATA[consolidation]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Evolution]]></category>
		<category><![CDATA[global ambition]]></category>
		<category><![CDATA[great]]></category>
		<category><![CDATA[imperative]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10932</guid>
		<description><![CDATA[The Indian pharmaceutical industry, long characterized by its formidable generic manufacturing capabilities, has decisively entered a robust phase of consolidation. In a landmark development, Torrent Pharmaceuticals has announced definitive agreements to acquire a controlling stake in JB Chemicals &#38; Pharmaceuticals for an &#8230; <a href="http://www.tapanray.in/the-great-indian-pharma-consolidation-a-strategic-imperative-for-global-ambition/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-great-indian-pharma-consolidation-a-strategic-imperative-for-global-ambition/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Closed Doors, Open Channels: India’s Ban on Medical Reps in Govt Hospitals Reshapes Pharma Engagement</title>
		<link>http://www.tapanray.in/closed-doors-open-channels-indias-ban-on-medical-reps-in-govt-hospitals-reshapes-pharma-engagement/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=closed-doors-open-channels-indias-ban-on-medical-reps-in-govt-hospitals-reshapes-pharma-engagement</link>
		<comments>http://www.tapanray.in/closed-doors-open-channels-indias-ban-on-medical-reps-in-govt-hospitals-reshapes-pharma-engagement/#comments</comments>
		<pubDate>Fri, 06 Jun 2025 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[email]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[Govt]]></category>
		<category><![CDATA[hospitals]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[India’s Ban MR]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reps]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10909</guid>
		<description><![CDATA[The June 3, 2025, directive from the Directorate General of Health Services (DGHS), banning medical representatives (MRs) from meeting doctors in central government hospitals, marks a pivotal policy shift in India&#8217;s evolving healthcare ecosystem. It signals a firm step toward &#8230; <a href="http://www.tapanray.in/closed-doors-open-channels-indias-ban-on-medical-reps-in-govt-hospitals-reshapes-pharma-engagement/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/closed-doors-open-channels-indias-ban-on-medical-reps-in-govt-hospitals-reshapes-pharma-engagement/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Being Eclectic – A Pharma Leadership Quality In The New Normal</title>
		<link>http://www.tapanray.in/being-eclectic-a-pharma-leadership-quality-in-the-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=being-eclectic-a-pharma-leadership-quality-in-the-new-normal</link>
		<comments>http://www.tapanray.in/being-eclectic-a-pharma-leadership-quality-in-the-new-normal/#comments</comments>
		<pubDate>Mon, 21 Jun 2021 00:00:07 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[ABBvie]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[eclectic]]></category>
		<category><![CDATA[gamification]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10531</guid>
		<description><![CDATA[It’s no-brainer that since the onset of Covid pandemic, digitalization initiative of many pharma companies in critical facets of business operations, has reached a new high. The process is now fast accelerating with the adoption of avant-garde ideas, and scalable &#8230; <a href="http://www.tapanray.in/being-eclectic-a-pharma-leadership-quality-in-the-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/being-eclectic-a-pharma-leadership-quality-in-the-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Focus On Core Competencies &#8211; Regardless of Generic Or Innovative Drug Business</title>
		<link>http://www.tapanray.in/focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business</link>
		<comments>http://www.tapanray.in/focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business/#comments</comments>
		<pubDate>Mon, 22 Feb 2021 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[antibiotics]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Carving-out]]></category>
		<category><![CDATA[cephalosporin]]></category>
		<category><![CDATA[cephalosporins]]></category>
		<category><![CDATA[competencies]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[Fortum]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regardless]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[shifting]]></category>
		<category><![CDATA[Spin-offs]]></category>
		<category><![CDATA[Splitting-off]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[strength]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Zinacef]]></category>
		<category><![CDATA[Zinnat]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10421</guid>
		<description><![CDATA[On February 11, 2021, by two different Press Releases, two global pharma majors – GSK and Novartis simultaneously made interesting announcements. Both were related to three generic cephalosporin antibiotics. GSK revealed, ‘it has reached an agreement with Sandoz &#8211; a &#8230; <a href="http://www.tapanray.in/focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>2020: Learnings From A Yearlong Catastrophic Disruption And Crystal-Gazing 2021</title>
		<link>http://www.tapanray.in/2020-learnings-from-a-yearlong-catastrophic-disruption-and-crystal-gazing-2021/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=2020-learnings-from-a-yearlong-catastrophic-disruption-and-crystal-gazing-2021</link>
		<comments>http://www.tapanray.in/2020-learnings-from-a-yearlong-catastrophic-disruption-and-crystal-gazing-2021/#comments</comments>
		<pubDate>Mon, 28 Dec 2020 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2020]]></category>
		<category><![CDATA[2021]]></category>
		<category><![CDATA[anti-infective]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[crystal-gazing]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[hubris]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[inorganic]]></category>
		<category><![CDATA[learning]]></category>
		<category><![CDATA[Meeting]]></category>
		<category><![CDATA[NDDS]]></category>
		<category><![CDATA[new drugs]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reputation]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[rollout]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Telehealth]]></category>
		<category><![CDATA[telemedicine]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[vaccines]]></category>
		<category><![CDATA[virtual]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10383</guid>
		<description><![CDATA[ Wishing All My Readers A Very Happy, Healthy, Peaceful and Prosperous 2021 Just a few days left for the year 2020 to merge with history. It will be remembered by all &#8211; as a year of all-round catastrophic global disruption. &#8230; <a href="http://www.tapanray.in/2020-learnings-from-a-yearlong-catastrophic-disruption-and-crystal-gazing-2021/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/2020-learnings-from-a-yearlong-catastrophic-disruption-and-crystal-gazing-2021/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Rare Strategic Acrobatic Feat in Covid Time</title>
		<link>http://www.tapanray.in/a-rare-strategic-acrobatic-feat-in-covid-time/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-rare-strategic-acrobatic-feat-in-covid-time</link>
		<comments>http://www.tapanray.in/a-rare-strategic-acrobatic-feat-in-covid-time/#comments</comments>
		<pubDate>Mon, 21 Dec 2020 00:00:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[acrobatic]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Alexion]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[comorbidity]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[feat]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[infected patients]]></category>
		<category><![CDATA[infection]]></category>
		<category><![CDATA[misdiagnosis]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[National Policy on rare diseases 2020]]></category>
		<category><![CDATA[new Coronavirus]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[rare diseases]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[time]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10376</guid>
		<description><![CDATA[‘Keep nose to the grindstone while lifting eyes to the hills.’ Quite a while ago, all-time global management guru – Peter Drucker used this essential acrobatic feat as an example, for the business strategists. This illustration signifies the criticality of harmonizing decisions &#8230; <a href="http://www.tapanray.in/a-rare-strategic-acrobatic-feat-in-covid-time/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-rare-strategic-acrobatic-feat-in-covid-time/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Enhancing Pharma Brand Experience In The New Normal</title>
		<link>http://www.tapanray.in/enhancing-pharma-brand-experience-in-the-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=enhancing-pharma-brand-experience-in-the-new-normal</link>
		<comments>http://www.tapanray.in/enhancing-pharma-brand-experience-in-the-new-normal/#comments</comments>
		<pubDate>Mon, 22 Jun 2020 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[approaches]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[ecosystem]]></category>
		<category><![CDATA[end-to-end]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[journey]]></category>
		<category><![CDATA[lockdown]]></category>
		<category><![CDATA[mapping]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[mindset]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[omnichannel]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[restart]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[touchpoint]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[unlock down]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10137</guid>
		<description><![CDATA[In these days of unprecedented and all-pervasive disruptions &#8211; almost in every facet of life &#8211; caused by an unknown virus, scramble to find an effective solution for saving lives and livelihoods, still continue. The discomfiture seems to be omnipresent &#8230; <a href="http://www.tapanray.in/enhancing-pharma-brand-experience-in-the-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/enhancing-pharma-brand-experience-in-the-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Would ‘Complex Generics’ Attract More ‘Authorized Generics’?</title>
		<link>http://www.tapanray.in/would-complex-generics-attract-more-authorized-generics/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=would-complex-generics-attract-more-authorized-generics</link>
		<comments>http://www.tapanray.in/would-complex-generics-attract-more-authorized-generics/#comments</comments>
		<pubDate>Mon, 28 Oct 2019 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advantages]]></category>
		<category><![CDATA[authorized]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Complex]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[initiatives]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[speciality]]></category>
		<category><![CDATA[spoilsport]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[traditional]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9761</guid>
		<description><![CDATA[Despite increasing numbers of alleged scams involving generic drugs, both in the United States and also in India, even involving many large generic drug manufacturers, the traditional generic drug market, keeps growing globally. Although, the current growth is in mid-single &#8230; <a href="http://www.tapanray.in/would-complex-generics-attract-more-authorized-generics/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/would-complex-generics-attract-more-authorized-generics/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
